Long-Term Risk Of Cervical Cancer Or Precursor For Type-Specific Human Papillomavirus In Chinese Women

Li DONG, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China
HU S. 1 , ZHANG Q. 1 , FENG R. 1 , PAN Q. 1 , ZHANG X. 1 , MA J. 2 , SHI S. 2 , ZHAO X. 1 , ZHANG L. 1 , ZHAO F. 1 , QIAO Y. 1

1 Department of Cancer Epidemiology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China
2 Xiangyuan Women and Children’s Hospital, Shanxi, China

Purpose: The role of high-risk human papillomavirus (HR-HPV) including HPV16 and 18 in predicting the cervical cancer and triaging the HPV positive women in the screening has been well demonstrated by many cohort studies and clinical trials. However these risk patterns of individual HPV types especially HPV 52 and 58 are not clear in China, therefore we evaluated the long-term risk for type-specific HPV in developing cervical cancer or precursors based on a population-based cervical cancer screening cohort in mainland China.
Methods:We analyzed the cohort database of Shanxi Provincial of Cervical Cancer Screening Study from 2005-2014, 1734 women aged 45–55 were screened by the Hybrid Capture 2 (HC2) and liquid based cytology (LBC) tests. The prevalence rate (PR) of individual type-specific HR-HPV tested by SPF10-LiPA V2 assay in HC2 positivity in 2005 was calculated and the cumulative incidence rates (CIR) of cervical intraepithelial neoplasia 2 or worse (CIN2+) for individual type-specific HR-HPV from 2005-2014 was estimated.
Results:Compared to HR-HPV negativity women(CIR= 2.1%), higher prevalence and risk of developing CIN2+ with 9 years following a positive test were observed in HPV16 (PR=32.8%; CIR=32.3%), HPV31 (PR=8.5%;CIR=27.8%), HPV58 (PR=12.8%; CIR=19.2%), HPV39 (PR=5.1%;CIR=18.2%), HPV52 (PR=15.7%;CIR=14.3%),  HPV33 (PR=9.8%;CIR=13.6%), and HPV18 (PR=8.9%;CIR=9.5%).
Conclusions:Our results indicate that HR-HPV genotyping may provide accurate risk stratification of HPV positive women. Specific prevalent and HR-HPV type in China including HPV16, 31, 58, 39, 52, 33 and 18, should be taken into consideration when the HPV-based cervical cancer screening and vaccination are applied.
Funding source:Our work was supported by the National Natural Science of Foundation of China (No 81322040).